2
Jan
2025

Investing in Biotech: David Schenkein on The Long Run

David Schenkein is today’s guest on The Long Run.

David is a general partner with GV. It’s the non-strategic corporate venture firm formerly known as Google Ventures. GV is backed by a single limited partner, Alphabet, and has $10 billion in assets under management in 400 active portfolio companies working in tech and life sciences.

David Schenkein, general partner, GV.

In this conversation, we talk about turning points in David’s career, the opportunities he sees at the nexus of technology and biology, and how he thinks about company culture. This last point is especially important to David, and deserves more public discussion.

Please join me and David Schenkein on The Long Run.

You may also like

A Two-Pronged Attack on Cancer: Claire Mazumdar on The Long Run
Finding Therapies in Long Non-Coding RNA: John Rinn on The Long Run
A New and Old Idea for Cardiovascular Disease & Diabetes: Ethan Weiss & Josh Lehrer on The Long Run
Biologic Drug Discovery Made Faster: Peyton Greenside on The Long Run